This discovery also opens a new therapeutic path and supports the rationale for using ESRP modulators in combination with AR antagonists for the treatment of advanced-stage prostate cancer to counteract the AR-antagonist-driven invasive phenotype. This evidence concerns the gene AR and Familial prostate cancer.